Skip to content

Harmony Biosciences Holdings, Inc. HRMY Additional Paid-In Capital

Additional Paid-In Capital at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$4.24B+8.1%
Alkermes logo
AlkermesALKS
$3.06B+4.9%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$1.43B+15.4%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$942.7M+29.5%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$536.3M-1.7%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$3.06B+3.7%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.98B-14.9%
Enterprise value$1.55B-24.9%
P/E13.6×-1.6×
P/S2.2×-0.9×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s additional paid-in capital?
Harmony Biosciences Holdings, Inc. (HRMY) reported additional paid-in capital of $717.37M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s additional paid-in capital changed year-over-year?
Harmony Biosciences Holdings, Inc.'s additional paid-in capital increased by 6.7% year-over-year, from $672.5M to $717.37M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s additional paid-in capital has grown at a 3.9% compound annual growth rate (CAGR), from $585.37M to $708.97M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.